menu
    • menu
    [{"orgOrder":0,"company":"Atom Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ABP-745","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Atom Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atom Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Atom Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atom Therapeutics","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Atom Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atom Therapeutics \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"9","companyTruncated":"Atom Therapeutics \/ China Medical System Holdings Limited"}]

    Find Clinical Drug Pipeline Developments & Deals by Atom Therapeutics

    Menu

    Atom Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Atom Therapeutics

                            China arrow
                            Florida Innovation
                            Not Confirmed

                            Atom Therapeutics

                            China arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABP-745

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of ABP-745 in Participants with an Acute Gout Flare

                            Details : ABP-745 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Arthritis, Gouty.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2025

                            Lead Product(s) : ABP-745

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Atom Therapeutics

                            China arrow
                            Florida Innovation
                            Not Confirmed

                            Atom Therapeutics

                            China arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : China Medical System Holdings Limited

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Atom, CMS Partner on Lingdolinurad for Gout, Hyperuricemia Treatment

                            Details : The collaboration aims for the commercialization of ABP-671 (lingdolinurad), a novel oral small molecule URAT1 inhibitor for the treatment of chronic gout and hyperuricemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : China Medical System Holdings Limited

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth